Gilead agrees to Sovaldi price cuts in Germany

Germany's statutory health insurer GKV-Spitzenverband said Gilead Sciences Inc. (NASDAQ:GILD) will offer a 12-week course of Sovaldi sofosbuvir for EUR 43,562 ($49,213), an 11% discount from its German list price of EUR 49,000 ($66,135) and a 44% discount from the regimen's wholesale acquisition price of $84,000 in the U.S. The discount will be retroactive to Jan. 23 and will last for three years (see BioCentury Extra, Feb. 4, 2014).

The discount is in line with what Gilead has said it expects for its HCV drugs in the U.S. this year. During its earnings call earlier this month, Gilead said it expected an adjusted gross to net of 46% in the U.S. for its HCV drugs Sovaldi and Harvoni ledipasvir/sofosbuvir. Last year, the company came to a similar agreement with France's Economic Committee of Health Products, pricing Sovaldi at EUR 41,000 ($51,058) for a 12-week course (see BioCentury Extra, Feb. 4). ...